60¢sixtycents

Regeneron Pharmaceuticals, Inc.REGN

Is REGN cheap right now? Every multiple below is scored against its own 10-year range, not a sector average.

$781.49-11.77 (-1.48%)24:00 UTC
NASDAQHealthcare

Company snapshot

Market Cap
$83B
Large-cap
+90%
2016 — today
10-Year Price
+107%
2016 — today
52-Week Range
$555.51$852.03
Current $781.49· 76%

Regeneron Pharmaceuticals discovers, develops, and manufactures treatments for diverse medical conditions. Its portfolio includes EYLEA (ophthalmic conditions), Dupixent (atopic dermatitis, asthma), Libtayo (cancer), Praluent (cardiovascular), Kevzara (rheumatoid arthritis), Inmazeb (Ebola), ARCALYST (periodic syndromes), ZALTRAP (colorectal cancer), and REGEN-COV. It maintains extensive R&D collaborations with partners like Sanofi, Bayer, and Roche to address unmet needs in oncology, immunology, and rare diseases.

Similar companies

Healthcare companies of comparable size to REGN
CompanyP/EDiv yield
ELVElevance Health Inc.18.61.6%
CICigna Corporation11.62.2%
HCAHCA Healthcare, Inc.14.30.7%
GSKGSK plc15.03.8%
SNYSanofi75.35.7%
MCKMcKesson Corporation23.60.4%
SYKStryker Corporation28.61.3%
BSXBoston Scientific Corporation17.5—

Healthcare companies of comparable size — each one shown against its own 10-year range, not a sector average. Browse all stocks we cover.

Valuation in context

P/E ratio
19.3
Around average
Around the 10-year average
Sector median 24.7below sector
P/B ratio
2.6
Historically cheap
Historically cheap relative to the last 10 years
Sector median 2.5in line with sector
EV / EBITDA
14.4
Below average
Below the 10-year average
Sector median 15.2in line with sector
Dividend Yield
0.5%
Historically high
Historically high relative to the last 10 years
Sector median 1.9%below sector
FCF Yield
4.2%
Around average
Around the 10-year average
Sector median -9.6%above sector
Free · No credit card needed

Get alerted when REGN is cheap

Set a free alert — we'll push you when P/E, yield, or other metrics cross a historical threshold.